
Barakat, MD, FASRS, on recognizing neovascular conversion in macular telangiectasia type 2, distinguishing it from neovascular AMD on imaging, and treating it without a robust evidence base.

Mark Barakat, MD, is a vitreoretinal surgeon and director of research at the Retina Macula Institute of Arizona, where he specializes in the surgical and medical management of complex retinal diseases. He is an active clinical trial investigator and a recognized voice in retinal drug development, with a focus on advancing next-generation therapies for conditions including neovascular age-related macular degeneration.

Barakat, MD, FASRS, on recognizing neovascular conversion in macular telangiectasia type 2, distinguishing it from neovascular AMD on imaging, and treating it without a robust evidence base.